# Bioactive Compounds and Nanodelivery Perspectives for Treatment of Cardiovascular Diseases
## 6 Conclusions  
Several bioactive compounds are being diagnosed and tested to see if they have the potential to improve human health. They have antioxidant, anti-inflammatory, and anticarcinogenic factors, in addition to physiological and cellular benefits that protect against infectious diseases and metabolic illnesses such as diabetes, cardiovascular disorder, and cancer. They are derived from plants, and their consumption in diets has been related to tremendous fitness outcomes, making them ideal assets for the manufacturing of new nutritional dietary supplements with extensive shielding and preservative abilities.  
Considering the high prevalence of CVDs worldwide, with a high level of morbidity and mortality, and excessive side effects of current therapies, the optimized alternative approaches are necessary for the prevention and/or treatment of these diseases. A large group of plant-derived bioactive compounds are used as alternative therapies for CVDs, which are summarized in this paper. They can be tailor-made to match the character and cultural preferences, to meet those lofty objectives, global and country-wide tasks to sell healthier, primarily plant-based diets. The role and significance of bioactive compounds for CVD treatment is still being explored, and its consequences must be established. Some polyphenols and flavonoids used as bioactive compounds have been shown to reduce CVD risk factors. Their antioxidant and anti-inflammatory properties are the most important characteristics that make them favorable candidates for CVDs treatment. Along with the detailed properties of bioactive compounds used in CVDs, the current review provides an overview of the therapeutic advantages of nanoformulations along with recent advancements in this field.  
The advantages of nano-delivery systems of bioactive compounds, recent preclinical studies, clinical trials, and nano-theranostic approaches are also discussed in this review, in order to offer a clearer understanding of the connection between bioactive compounds and CVD prevention, diagnostics, and treatment. Although the reported success of preclinical studies is related to the effectivity of nanoformulations and theranostic nanoplatforms, the translational approach to clinical sectors remains poorly explored, as the therapeutic applications of nano-phytomedicines in CVDs are still in their initial clinical phases. Nanotechnologies will provide a new window in the area of CVDs with the opportunity to achieve effective treatment, better prognosis, and fewer adverse effects on non-target tissues. However, further research is required for the development of low-cost nanoformulations and their effective usage, along with research in the toxicological approach.  
Conceptualization, R.K.S. and S.C.; data curation, R.K.S., A.G., E.A.Y.; writing--original draft preparation, R.K.S., A.G., E.A.Y.; writing--review and editing, R.K.S. and S.C.; funding acquisition, S.C. All authors have read and agreed to the published version of the manuscript. This research received no external funding.  
Not applicable.  
The authors R.K.S. and A.G. are grateful to [PERSON], Chancellor, Chitkara University, Rajpura, Patiala, India and [PERSON], Chancellor, Chitkara University, Rajpura, Patiala, India, for support and institutional facilities.  
The authors declare no conflict of interest, financial or otherwise.